FDA Approves MIMRYLO (Rusfertide), a Hepcidin-Mimetic Peptide for Polycythemia VeraThe FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.
